Menu
Search
|

Menu

Close
X

WAVE Life Sciences Ltd WVE.OQ (NASDAQ Stock Exchange Global Market)

36.90 USD
-- (--)
As of Jul 13
chart
Previous Close 36.90
Open --
Volume --
3m Avg Volume 63,512
Today’s High --
Today’s Low --
52 Week High 55.95
52 Week Low 15.15
Shares Outstanding (mil) 29.11
Market Capitalization (mil) 1,073.99
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
3
FY16
1
FY15
0
EPS (USD)
FY18
-1.262
FY17
-3.842
FY16
-2.407
FY15
-1.594
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.20
Price to Sales (TTM)
vs sector
241.35
8.07
Price to Book (MRQ)
vs sector
9.39
4.28
Price to Cash Flow (TTM)
vs sector
--
22.38
Total Debt to Equity (MRQ)
vs sector
0.00
17.39
LT Debt to Equity (MRQ)
vs sector
0.00
13.21
Return on Investment (TTM)
vs sector
-85.64
13.23
Return on Equity (TTM)
vs sector
-102.39
15.28

EXECUTIVE LEADERSHIP

Gregory Verdine
Independent Chairman of the Board, Since 2012
Salary: $8,525.00
Bonus: --
Paul Bolno
President, Chief Executive Officer, Director, Since 2013
Salary: $490,000.00
Bonus: $329,000.00
Keith Regnante
Chief Financial Officer, Since 2016
Salary: $120,000.00
Bonus: --
Christopher Francis
Senior Vice President, Corporate Development & Portfolio Management, Since 2017
Salary: $131,042.00
Bonus: --
Chandra Vargeese
Senior Vice President, Head of Drug Discovery, Since 2014
Salary: $118,750.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

7 Straits View #12-00,
Marina One East Tower
    018936

Phone:

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics, which the Company is developing are stereopure. A stereopure oligonucleotide includes molecules with atoms arranged in three-dimensional orientations at each linkage. The Company has three programs in Huntington's disease (HD) and Duchenne Muscular Dystrophy (DMD), and three additional development candidates.

SPONSORED STORIES